Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

JNJ 93.92 +0.74 (0.79%)
price chart
Johnson & Johnson Prostate Cancer Drug Impresses
A new study shows that Johnson & Johnson's prostate cancer pill Zytiga dramatically slows the progression of the disease in men who are not yet sick enough to start chemotherapy.
Johnson & Johnson Latest Company To Break Away From ALEC
Johnson & Johnson is the latest company to break away from the American Legislative Exchange Council (ALEC). On June 12, Johnson & Johnson announced it would stop funding the group that has pushed states to pass voter ID and stand-your-ground ...
Johnson & Johnson Should Split Up Says Goldman
Johnson & Johnson should split into three companies, which could value health-care conglomerate at $76 a share, up more than 20% from current price of $62, Goldman Sachs says.
Johnson & Johnson: Breaking Up Is Not Hard To Do  Seeking Alpha
Johnson & Johnson's $19.7B Synthes Deal: A Surprise Earnings Boost
NEW YORK, NY - MAY 07: Managing Editor of Fortune Magazine Andy Serwer, former Chairman and CEO of Continental Airlines Gordon Bethune, Chairman and CEO, JPMorgan Chase & Co, James 'Jamie' Dimon and CEO of Johnson & Johnson Alex ...
Johnson & Johnson Announces Completion of Synthes Acquisition  PR Newswire (press release)
Johnson & Johnson's Synthes Deal Revives Foreign Tax Debate
Johnson & Johnson Receives U.S. Regulatory Clearance for Synthes Acquisition ...
NEW BRUNSWICK, N.J., June 12, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received U.S.
Johnson & Johnson: Synthes deal closes Thursday  BusinessWeek
Johnson & Johnson Breaks Above 200-Day Moving Average - Bullish for JNJ  Forbes
Cramer: Johnson & Johnson Could Unlock Value by Splitting Up
Take Johnson & Johnson, for example. The New Brunswick, N.J.-based company makes everything from Band-Aids and Tylenol to knee implants and prescription drugs, all of which are fairly resistant to a global slowdown, Cramer said.
Johnson & Johnson diabetes drug tops older therapies in studies
An experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than Merck & Co's Januvia and an older common treatment, glimepiride, according to data from a pair of late stage clinical trials.
BREAKING: Johnson & Johnson Drops ALEC
Pharmaceutical giant Johnson and Johnson announced today that they are dropping their membership from the American Legislative Exchange Council (ALEC).
Johnson & Johnson wins US approval to buy Synthes
Johnson & Johnson will sell its system for surgically treating serious wrist fractures, and related assets, to Biomet Inc LVBHAB.
Johnson & Johnson's Favorable Ratings: Does The Market Prefer Trademarks Or ...
Analysts are starting to like Johnson & Johnson again. (Disclaimer: I have now exhausted my knowledge of markets.) What drives the value of companies these days, brand power (trademarks) or brain power (patents)?